139 related articles for article (PubMed ID: 27805257)
1. Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Wakimoto H; Harada K; Arai T; Maeda T; Irisawa R; Tsuboi R
Int J Dermatol; 2017 Feb; 56(2):e33-e35. PubMed ID: 27805257
[No Abstract] [Full Text] [Related]
2. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
[No Abstract] [Full Text] [Related]
3. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
4. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
Gupta M; Huang V; Linette G; Cornelius L
Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
[No Abstract] [Full Text] [Related]
5. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
7. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
[No Abstract] [Full Text] [Related]
8. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
9. [Vemurafenib (Zelboraf) in the therapy of melanoma].
Liszkay G
Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
[TBL] [Abstract][Full Text] [Related]
10. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
Sachse MM; Wagner G
Br J Dermatol; 2014 Feb; 170(2):475-7. PubMed ID: 24117280
[No Abstract] [Full Text] [Related]
11. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
13. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
14. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
[TBL] [Abstract][Full Text] [Related]
15. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
[No Abstract] [Full Text] [Related]
16. Genetic profiling of BRAF inhibitor-induced keratoacanthomas reveals no induction of MAP kinase pathway expression.
Kulkarni RP; Plaisier S; Ra SH; Li X; Lee DJ; Hillman JD; Binder SW
J Invest Dermatol; 2013 Mar; 133(3):830-833. PubMed ID: 23014342
[No Abstract] [Full Text] [Related]
17. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
18. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
Mangold AR; Bryce A; Sekulic A
J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
[No Abstract] [Full Text] [Related]
19. Vemurafenib-induced hypertension: is it real?
Balakan O; Babacan T; Altundag K
J BUON; 2013; 18(2):545. PubMed ID: 23818377
[No Abstract] [Full Text] [Related]
20. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
